[
  {
    "ts": null,
    "headline": "Danaher Corp. stock outperforms competitors on strong trading day",
    "summary": "Danaher Corp. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=cb14d6f1ce098db5cc4ca6d27cbef34290f7327f3fd4f8cd049775390f30a129",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745944560,
      "headline": "Danaher Corp. stock outperforms competitors on strong trading day",
      "id": 134149348,
      "image": "",
      "related": "DHR",
      "source": "MarketWatch",
      "summary": "Danaher Corp. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=cb14d6f1ce098db5cc4ca6d27cbef34290f7327f3fd4f8cd049775390f30a129"
    }
  },
  {
    "ts": null,
    "headline": "Kytopen and Aldevron Expedite Cell Therapy Manufacturing Through Their Collaborative CRISPR-mediated Cellular Engineering Workflow",
    "summary": "Kytopen Corp., a leader in providing non-viral, continuous flow cellular engineering technologies and Aldevron, a leading global manufacturer serving organizations in the gene editing, mRNA vaccine and therapeutics, viral gene therapy, and modified gene therapy spaces; today announced, a joint marketing agreement aimed at enhancing the workflow solutions for cell therapy manufacturers. The collaboration will focus on the joint promotion of the synergies achieved by combining the Aldveron Nanopla",
    "url": "https://finnhub.io/api/news?id=9cf8f2e5d129699217e6d92ed801704e4e897645a74366c0d690e07198fb7a8e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745935620,
      "headline": "Kytopen and Aldevron Expedite Cell Therapy Manufacturing Through Their Collaborative CRISPR-mediated Cellular Engineering Workflow",
      "id": 134131237,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DHR",
      "source": "Yahoo",
      "summary": "Kytopen Corp., a leader in providing non-viral, continuous flow cellular engineering technologies and Aldevron, a leading global manufacturer serving organizations in the gene editing, mRNA vaccine and therapeutics, viral gene therapy, and modified gene therapy spaces; today announced, a joint marketing agreement aimed at enhancing the workflow solutions for cell therapy manufacturers. The collaboration will focus on the joint promotion of the synergies achieved by combining the Aldveron Nanopla",
      "url": "https://finnhub.io/api/news?id=9cf8f2e5d129699217e6d92ed801704e4e897645a74366c0d690e07198fb7a8e"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer on Danaher Corporation (DHR): From Best to Worst Amid China Struggles",
    "summary": "We recently published a list of Jim Cramer Talks About Elon Musk & Discusses These 11 Stocks. In this article, we are going to take a look at where Danaher Corporation (NYSE:DHR) stands against other stocks that Jim Cramer recently discussed. In a recent appearance on CNBC’s Squawk on the Street, Jim Cramer commented that […]",
    "url": "https://finnhub.io/api/news?id=09f0c4f1f6f08c1b9b00a6241c2cfc5f7b39a31b7990fa6d8718423f76deb993",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745929512,
      "headline": "Jim Cramer on Danaher Corporation (DHR): From Best to Worst Amid China Struggles",
      "id": 134131238,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DHR",
      "source": "Yahoo",
      "summary": "We recently published a list of Jim Cramer Talks About Elon Musk & Discusses These 11 Stocks. In this article, we are going to take a look at where Danaher Corporation (NYSE:DHR) stands against other stocks that Jim Cramer recently discussed. In a recent appearance on CNBC’s Squawk on the Street, Jim Cramer commented that […]",
      "url": "https://finnhub.io/api/news?id=09f0c4f1f6f08c1b9b00a6241c2cfc5f7b39a31b7990fa6d8718423f76deb993"
    }
  },
  {
    "ts": null,
    "headline": "Baron Health Care Fund Q1 2025 Top Contributors And Detractors",
    "summary": "Baron Health Care Fund declined 2.54% in Q1 2025. Who were the leaders and laggards? Click here to find out.",
    "url": "https://finnhub.io/api/news?id=64360e2ab5d7c801187183c998d5cb1993bbd2f845ff25b1630d3ed1c274fe69",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745926200,
      "headline": "Baron Health Care Fund Q1 2025 Top Contributors And Detractors",
      "id": 134127928,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1345347757/image_1345347757.jpg?io=getty-c-w1536",
      "related": "DHR",
      "source": "SeekingAlpha",
      "summary": "Baron Health Care Fund declined 2.54% in Q1 2025. Who were the leaders and laggards? Click here to find out. ",
      "url": "https://finnhub.io/api/news?id=64360e2ab5d7c801187183c998d5cb1993bbd2f845ff25b1630d3ed1c274fe69"
    }
  }
]